golimumab,guselkumab
janssen
[]
 a fair number of oncology trials also do this in early-phase or early stages of a multi-stage trial, with pretty permissive/relaxed alpha then more stringent parameters used in pivotal, late-phase setting so think fair to do - but agree we should be a bit cautious about numbers
Clinical Research Fellow for PROFILE trial @ProfileCrohn ???? MRC/UKRI Doctoral Candidate @MRCCTU ????  Editorial Fellow/Associate Editor @IBDJournals